Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study

NCT01272128 · clinicaltrials.gov ↗

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Interferon beta-1a

Sponsor

Biogen